TL;DR
Get sports gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Craig Hockenberry’s Oct. 28 post describes his experience with lymphoma treatment, including chemotherapy, pneumonia and ongoing nerve damage. He says that after completing infusions in May, his strength and stamina began returning and he later noticed signs of nerve recovery; the cause and extent of that recovery remain uncertain in the supplied report.
Hockenberry said his treatment began with a six-week course of **weekly lumbar punctures**, which ended in late January. He wrote that doctors removed spinal fluid for analysis and replaced it with methotrexate. He experienced severe headaches afterward and said lying flat helped ease them. He then received infusions of **bendamustine and rituximab** on a 28-day cycle.
He described changes in taste, fatigue and loss of muscle mass during treatment, as well as a **50-pound weight loss over a couple of months**. He said he had to increase his food intake to five meals a day, despite finding that food tasted unpleasant. The account is personal testimony; it does not provide clinical records or a broader assessment of how other patients might respond.
In March, Hockenberry said he developed pneumonia while his immune system was weakened and his blood oxygen level fell below 90%. He also reported an episode of atrial fibrillation detected by his Apple Watch. He wrote that antibiotics treated the pneumonia and that his doctor offered to skip the next chemotherapy cycle, but he chose to continue. After his last infusions in May, he said his appetite, strength and walking distance gradually improved.
Treatment Complications and Recovery
Hockenberry’s account provides a first-person view of how **lymphoma treatment affected daily life** beyond the infusion appointments: fatigue, major weight loss, altered taste, mobility problems and an infection during a period of weakened immunity. His description of pneumonia and a reported low oxygen reading illustrates why complications during cancer treatment may require prompt medical attention, though his experience cannot predict another person’s risks or outcome.
The update also records a gradual return to activity alongside unresolved symptoms. Hockenberry said he used walking sticks and took daily walks despite balance and nerve problems, with distances increasing during recovery. That progression is his individual experience, not medical guidance for patients. Treatment decisions, exercise and responses to symptoms should be discussed with a person’s clinical team.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Coleman Skydome 6-Person Camping Tent with Rainfly
As an affiliate, we earn on qualifying purchases.
From Spinal Treatment to Infusions
The post describes several stages of treatment. Hockenberry said the weekly spinal procedures lasted **six weeks and ended in late January**, followed by chemotherapy infusions on a 28-day schedule. He reported that the first week after each infusion was especially difficult and that he generally began to feel more like himself by the middle of the second week.
He also described nerve damage that was present before the lymphoma was discovered. During treatment, he said his gait and balance remained impaired, stairs were difficult, and numbness and tingling continued. After finishing infusions in **May**, he reported that these problems did not immediately disappear, even as his energy and walking capacity started to return.
“I’m writing this post from a hospital bed. And I couldn’t be happier.”
— Craig Hockenberry, in his Oct. 28 post
Cause of Nerve Changes Remains Unclear
The supplied post excerpt ends as Hockenberry begins to discuss a possible link between chemotherapy infusions and the changes he felt in his spine. It does not include the rest of that explanation, a confirmed medical cause, or details of any clinical evaluation. His description of a new sensation in his legs is **his observation**, not confirmation of nerve repair.
The excerpt also does not specify the precise lymphoma diagnosis, the overall treatment plan, later test results or why he was in a hospital bed when he wrote the update. It gives no current assessment of his cancer status or long-term recovery. Those points should not be inferred from the account.
Further Clinical Updates Needed
Hockenberry’s post describes recovery after his final infusions in **May**, but the supplied material does not set out a next appointment, scan or treatment milestone. Any clearer account of his nerve symptoms, lymphoma status and the reason for his hospital stay would depend on further information from Hockenberry or his medical team.
For now, the update establishes what he reported experiencing and how he described his recovery; it does not establish a prognosis or confirm the cause of the later leg sensations. Readers should treat the account as a personal report, not as medical advice or a guide to what others undergoing chemotherapy should expect.
Key Questions
Who wrote the health update?
Craig Hockenberry wrote the personal post, published on Furbo.org on Oct. 28, 2026.
What treatment did Hockenberry describe?
He described a six-week course of weekly spinal procedures involving methotrexate, followed by 28-day-cycle infusions of bendamustine and rituximab. The post excerpt does not give a full medical history or treatment record.
What complications did he report?
Hockenberry reported severe headaches after the spinal procedures, fatigue, changes in taste, muscle loss and substantial weight loss. He also said he developed pneumonia in March while his immune system was weakened and experienced an episode of atrial fibrillation detected by his Apple Watch.
Did he say his nerve damage had recovered?
No confirmed recovery is established in the supplied excerpt. He described a new sensation in the backs of his legs after his infusions ended and said he thought it might signal nerve changes, but the excerpt provides no clinical confirmation or assessment of the cause.
Source: hn
